Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by westcoast1000on Jun 13, 2023 1:05pm
233 Views
Post# 35494060

RE:Some numbers to chew on….Roche & onc

RE:Some numbers to chew on….Roche & oncThanks for the info on tecentriq, CF.

Here are a few further points. Tencentriq in licensed for use in a variety of cancers already. It is possible that pela could help improve outcomes in an array of them.

Also, there is an additional point to stress about timing. Not only are the results likely to be stronger the longer the results take for OS in panc and mBC, the higher value the company. The biggest gap in cancer care at present is durability, or the length of survival with reasonable quality of life. The longer the OS takes to be available, the greater the durability of treatment and length of life. 

Hence, it is hard to determine the value of the company without knowing the OS results. From the waterfall graphs from former trials the OS adavantage only becomes apparent after a period of time.

That is my perspective why we are waiting.

Others will say that we are waiting because the company is a scam that endures to pay the management and Matt is the poster boy for running a "shite" company that just takes money on lies.

This last perspective, apparent among bashers on ST and Yahoo, does not fit with the results, which cannot be fabricated or talked away by reference to the current share price. 


<< Previous
Bullboard Posts
Next >>